Reduction of Chemotherapy Associated Accelerated Aging by ImmortaSome™ Personalized Exosome Rejuvenation

Immorta Bio Inc Announces Proof-of-Concept Findings Leveraging Natural Nanoparticles to Rejuvenate Damaged Tissue

MIAMI, March 10, 2025 /PRNewswire/ — Immorta Bio Inc, a Scientific Longevity Company dedicated to “Treating Diseases of Aging and Aging as Disease™” announced today filing of a patent application covering its ImmortaSome™ personalized exosome technology. 

Laboratory and animal studies have shown that administration of ImmortaSome™ exosomes results in reduction of cellular aging in response to agents that normal accelerate aging such as chemotherapy. 

ImmortaSome exosomes are generated in a patient specific manner in that patient blood is extracted, converted into Immortal Stem Cells called “Personal Regenerative Cells” (PRC).  The PRC are grown in the laboratory and converted to mesenchymal stem cells of a defined biological age, which are utilized as the source of the ImmortaSome™ exosomes.

“Exosome therapeutics are a revolution in Longevity and Anti-Aging Medicine.  They transfer many of the regenerative activities of stem cells and do not possess the limitations associated with cell administration such as potential neoplasia or pulmonary accumulation,” said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio. “Unfortunately, exosomes are limited by the fact they need to be collected from young sources.  The ImmortaSome exosomes are generated as ‘young’ exosomes from cells of the same patient that have been made ‘young’ in the laboratory.”

Immorta Bio has previously demonstrated reduction of cancer by killing “aged” or “senescent” cells that surround tumors¹ (https://medcraveonline.com/JSRT/can-senolysis-be-used-to-overcome-tumor-immune-evasion.html). The currently announced technology provides means of reducing side effects of cancer therapies, as well as potentially will be applicable to aging caused by other means.

“As a biotechnology corporation we need to identify as quickly as possible the therapeutic potency of our products,” said Dr. Boris Reznik, CEO and Chairman of Immorta Bio. “By focusing on chemotherapy associated aging we can rapidly enter clinical trials and obtain anti-aging efficacy data of our product in a highly accelerated manner.  Successful results in this indication will allow us to expand to treating other causes of aging.”

About Immorta Bio Immorta Bio Inc., a scientific longevity company focused on “Treating Diseases of Aging and Treating Aging as Disease™,” leverages anti-aging technologies to tackle pressing medical challenges, from advanced cancers to other age-related conditions. To learn more about Immorta Bio’ research initiatives, visit immortabio.com, LinkedIn and X.

Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com 
+1 305-632-2939 
@immortabio 

¹ Can senolysis be used to overcome tumor immune evasion?” Journal of Stem Cell Research & Therapeutics. Available at https://medcraveonline.com/JSRT/can-senolysis-be-used-to-overcome-tumor-immune-evasion.html.

View original content to download multimedia:https://www.prnewswire.com/news-releases/reduction-of-chemotherapy-associated-accelerated-aging-by-immortasome-personalized-exosome-rejuvenation-302397017.html

SOURCE Immorta Bio Inc.